Re-evaluating the treatment of acute optic neuritis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 7, 2015, Pages 799-808

  Bennett, Jeffrey L ^a   Nickerson, Molly ^b   Costello, Fiona ^c   Sergott, Robert C ^d   Calkwood, Jonathan C ^e   Galetta, Steven L ^f   Balcer, Laura J ^f   Markowitz, Clyde E ^g   Vartanian, Timothy ^h   Morrow, Mark ⁱ   Moster, Mark L ^d   Taylor, Andrew W ^j   Pace, Thaddeus W W ^k   Frohman, Teresa ^l   Frohman, Elliot M ^l  

^a UNIVERSITY OF COLORADO   (United States)

^b Questcor Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Minneapolis Clinic of Neurology   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h ROCKEFELLER UNIVERSITY   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ARIZONA   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; CORTICOTROPIN; ERYTHROPOIETIN; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN; LINGO1 ANTIBODY; MEMANTINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; PREDNISONE; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ACNE; ACUTE PANCREATITIS; ANKLE EDEMA; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; CONVALESCENCE; DEMYELINATION; DEPRESSION; DEPTH PERCEPTION; DRUG EFFICACY; DRUG ERUPTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACE EDEMA; HEADACHE; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMAGING; IMMUNE INJURY; INFUSION RELATED REACTION; LOW DRUG DOSE; MOVEMENT PERCEPTION; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NONHUMAN; OPTIC NERVE INJURY; OPTIC NEURITIS; PERCEPTION DISORDER; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER; STOMACH DISCOMFORT; TISSUE INJURY; TREATMENT RESPONSE; VISUAL DISORDER; ACUTE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMAPHERESIS; SCANNING LASER POLARIMETRY;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ERYTHROPOIETIN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMA EXCHANGE; SCANNING LASER POLARIMETRY;

EID: 84939229074     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308185     Document Type: Review

References (81)

1. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H). Lancet 1961; 2: 1120-2.
2. Rawson MD, Liversedge LA. Treatment of retrobulbar neuritis with corticotrophin. Lancet 1969; 2: 222.
3. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev 2012; 4: CD001430.
4. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326: 581-8.
5. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol 1993; 111: 773-5.
6. Hickman SJ, Kapoor R, Jones SJ, et al. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry 2003; 74: 1139-41.
7. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med 1993; 329: 1764-9.
8. Goodin DS Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999; 18: 53-63.
9. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64: 804-10.
10. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-22.
11. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63: 1081-3.
12. Schattling B, Steinbach K, Thies E, et al. TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2012; 18: 1805-11.
13. Diem R, Sättler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005; 128: 375-85.
14. Suhs KW, Hein K, Sattler MB, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 2012; 72: 199-210.
15. Blazek P, Davis SL, Greenberg BM, et al. Objective characterization of the relative afferent pupillary defect in MS. J Neurol Sci 2012; 323: 193-200.
16. Frohman AR, Schnurman Z, Conger A, et al. Multifocal visual evokedpotentials are influenced by variable contrast stimulation in MS. Neurology 2012; 79: 797-801.
17. Frohman TC, Beh SC, Saidha S, et al. Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology 2013; 81: 545-51.
18. Ratchford JN, Saidha S, Sotirchos ES, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology 2013; 80: 47-54.
19. Petzold A, Plant GT. The diagnostic and prognostic value of neurofilament heavy chain levels in immune-mediated optic neuropathies. Mult Scler Int 2012; 2012: 217802.
20. Saidha S, Syc SB, Ibrahim MA, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134: 518-33.
21. Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry 2004; 75: 1178-80.
22. Chatziralli IP, Moschos MM, Brouzas D, et al. Evaluation of retinal nerve fibre layer thickness and visual evoked potentials in optic neuritis associated with multiple sclerosis. Clin Exp Optom 2012; 95: 223-8.
23. Frohman EM, Fujimoto JG, Frohman TC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 2008; 4: 664-75.
24. Zaveri MS, Conger A, Salter A, et al. Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol 2008; 65: 924-8.
25. Kupersmith MJ, Mandel G, Anderson S, et al. Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci 2011; 308: 117-23.
26. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006; 59: 963-9.
27. Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010; 133: 2592-602.
28. Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006; 113: 324-32.
29. Villoslada P, Cuneo A, Gelfand J, et al. Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler 2012; 18: 991-9.
30. Hickman SJ, Toosy AT, Miszkiel KA, et al. Visual recovery following acute optic neuritis - a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251: 996-1005.
31. Inglese M, Ghezzi A, Bianchi S, et al. Irreversible disability and tissue loss in multiple sclerosis: a conventional and magnetization transfer magnetic resonance imaging study of the optic nerves. Arch Neurol 2002; 59: 250-55.
32. Hickman SJ, Coulon O, Parker GJ, et al. Application of a B-spline active surface technique to the measurement of cervical cord volume in multiple sclerosis from three-dimensional MR images. J Magn Reson Imaging 2003; 18: 368-71.
33. Naismith RT, Xu J, Tutlam NT, et al. Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities. Neurology 2009; 72: 589-94.
34. Glisson CC, Galetta SL. Nonconventional optic nerve imaging in multiple sclerosis. Neuroimaging Clin N Am 2009; 19: 71-9.
35. Thorpe J, Barker G, Jones S, et al. Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. J Neurol Neurosurg Psychiatry 1995; 59: 487-92.
36. Hickman SJ, Toosy AT, Jones SJ, et al. Serial magnetization transfer imaging in acute optic neuritis. Brain 2004; 127: 692-700.
37. Naismith RT, Xu J, Tutlam NT, et al. Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 2010; 74: 1702-10.
38. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54: 1720-5.
39. Klistorner A, Arvind H, Nguyen T, et al. Multifocal VEP and OCT in optic neuritis: a topographical study of the structure-function relationship. Doc Ophthalmol 2009; 118: 129-37.
40. Henderson AP, Altmann DR, Trip SA, et al. Early factors associated with axonal loss after optic neuritis. Ann Neurol 2011; 70: 955-63.
41. Sutter EE, Bearse MA Jr The optic nerve head component of the human ERG. Vision Res 1999; 39: 419-36.
42. Modvig S, Degn M, Horwitz H, et al. Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS ONE 2013; 8: e77163.
43. Pasol J, Feuer W, Yang C, et al. Phosphorylated neurofilament heavy chain correlations to visual function, optical coherence tomography, and treatment. Mult Scler Int 2010; 2010: 542691.
44. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-89.
45. Tsoi VL, Hill KE, Carlson NG, et al. Immunohistochemical evidence of inducible nitric oxide synthase and nitrotyrosine in a case of clinically isolated optic neuritis. J Neuroophthalmol 2006; 26: 87-94.
46. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol 2007; 275: 62-70.
47. Muls N, Jnaoui K, Dang HA, et al. Upregulation of IL-17, but not of IL-9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol 2012; 243: 73-80.
48. Xu L, Xu Z, Xu M. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis. Clin Exp Immunol 2009; 158: 26-30.
49. Braitch M, Harikrishnan S, Robins RA, et al. Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009; 119: 239-45.
50. Clarner T, Parabucki A, Beyer C, et al. Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. J Neuroendocrinol 2011; 23: 601-11.
51. Diem R, Demmer I, Boretius S, et al. Autoimmune optic neuritis in the common marmoset monkey: comparison of visual evoked potentials with MRI and histopathology. Invest Ophthalmol Vis Sci 2008; 49: 3707-14.
52. Catania A, Gatti S, Colombo G, et al. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56: 1-29.
53. Lee DJ, Taylor AW. Following EAU recovery there is an associated MC5r-dependent APC induction of regulatory immunity in the spleen. Invest Ophthalmol Vis Sci 2011; 52: 8862-7.
54. Lindqvist N, Napankangas U, Lindblom J, et al. Proopiomelanocortin and melanocortin receptors in the adult rat retino-tectal system and their regulation after optic nerve transection. Eur J Pharmacol 2003; 482: 85-94.
55. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007; 114: 810-15.
56. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 2009; 72: 1077-82.
57. Raff MC, Lillien LE, Richardson WD, et al. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988; 333: 562-5.
58. Liedtke W, Edelmann W, Bieri PL, et al. GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination. Neuron 1996; 17: 607-15.
59. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012; 135: 886-99.
60. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-91.
61. Esfahani MR, Harandi ZA, Movasat M, et al. Memantine for axonal loss of optic neuritis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 863-9.
62. Kidd D, Burton B, Plant GT, et al. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003; 126: 276-84.
63. Arndt C, Labauge P, Speeg-Schatz C, et al. Recurrent inflammatory optic neuropathy. J Fr Ophtalmol 2008; 31: 363-7.
64. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010; 81: 109-11.
65. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-43.
66. An X, Kezuka T, Usui Y, et al. Suppression of experimental autoimmune optic neuritis by the novel agent fingolimod. J Neuroophthalmol 2013; 33: 143-8.
67. Linker RA, Lee D-H, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134: 678-92.
68. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-15.
69. Rawson MD, Liversedge LA, Goldfarb G. Treatment of acute retrobulbar neuritis with corticotrophin. Lancet 1966; 2: 1044-6.
70. Bowden AN, Bowden PM, Friedmann AI, et al. A trial of corticotrophin gelatin injection in acute optic neuritis. J Neurol Neurosurg Psychiatry 1974; 37: 869-73.
71. Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998; 50: 230-7.
72. Achiron A. Winning combination: the additive/synergistic benefits of IVIg in corticosteroid refractory optic neuritis. Eur J Neurol 2008; 15: 1145.
73. Tselis A, Perumal J, Caon C, et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008; 15: 1163-7.
74. Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand 2012; 126: 103-8.
75. Fraser CL, Holder GE. Electroretinogram findings in unilateral optic neuritis. Doc Ophthalmol 2011; 123: 173-8.
76. Reich DS, Smith SA, Gordon-Lipkin EM, et al. Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol 2009; 66: 998-1006.
77. Trip SA, Wheeler-Kingshott C, Jones SJ, et al. Optic nerve diffusion tensor imaging in optic neuritis. Neuroimage 2006; 30: 498-505.
78. Kupersmith MJ, Kardon R, Durbin M, et al. Scanning laser polarimetry reveals status of RNFL integrity in eyes with optic nerve head swelling by OCT. Invest Ophthalmol Vis Sci 2012; 53: 1962-70.
79. Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007; 69: 2085-92.
80. Fraser CL, Klistorner A, Graham SL, et al. Multifocal visual evoked potential analysis of inflammatory or demyelinating optic neuritis. Ophthalmology 2006; 113: 315-23.
81. Salter AR, Conger A, Frohman TC, et al. Retinal architecture predicts pupillary reflex metrics in MS. Mult Scler 2009; 15: 479-86.